Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leach, J. P.
Right arrow Articles by Hart, I. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leach, J. P.
Right arrow Articles by Hart, I. K.
Neurology 1999;52:738
© 1999 American Academy of Neurology
Articles

Improvement in adult-onset Rasmussen’s encephalitis with long-term immunomodulatory therapy

J. P. Leach, MRCP, D. W. Chadwick, FRCP, J. B. Miles, FRCS and I. K. Hart, FRCP(G)

From the Department of Neurological Science (Drs. Chadwick and Hart), University of Liverpool, and Walton Centre for Neurology and Neurosurgery (Drs. Leach, Chadwick, Miles, and Hart), Liverpool, UK.

Address correspondence and reprint requests to Dr. Ian Hart, University of Liverpool, Department of Neurological Science, Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7LJ, UK.

OBJECTIVE: To study the immediate and chronic effects of high-dose, long-term human IV immunoglobulin (hIVIg) therapy in two patients with advanced adult-onset Rasmussen’s encephalitis (RE).

BACKGROUND: Despite advances in our understanding of the autoimmune pathogenesis of RE, medical options for chronic treatment are limited.

METHODS: In an open-label treatment trial, treatment started with monthly cycles of high-dose hIVIg (0.4 g/kg/d for 5 days) followed by maintenance therapy (0.4 g/kg 1 day each month) after the patients’ conditions began to improve. Outcome measures included clinical, psychological, functional, and laboratory assessments before and at relevant intervals throughout 1 year of treatment.

RESULTS: In both patients, unrelenting pretreatment deterioration halted, and after this they displayed striking improvements in seizure control, hemiparesis, and cognition that produced useful recovery of function. Improvements were delayed until after 2 to 4 monthly cycles of high-dose hIVIg and continued when patients switched to maintenance treatment. Their recoveries were accompanied by increased cerebral perfusion on interictal SPECT and suppression of inflammatory markers in CSF.

CONCLUSIONS: hIVIg can be a useful, possibly disease-modifying, long-term therapy for adult-onset RE that should be considered before radical surgery is performed. Because improvements can be delayed, we propose guidelines for intensive and prolonged trials of immunomodulatory therapy in adults with this syndrome.




This article has been cited by other articles:


Home page
 NeurologyHome page
A. Gambardella, F. Andermann, S. Shorvon, E. Le Piane, and U. Aguglia
Limited chronic focal encephalitis: Another variant of Rasmussen syndrome?
Neurology, January 29, 2008; 70(5): 374 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
R Kneen and R E Appleton
Alternative approaches to conventional antiepileptic drugs in the management of paediatric epilepsy
Arch. Dis. Child., November 1, 2006; 91(11): 936 - 941.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
C. G. Bien, T. Granata, C. Antozzi, J. H. Cross, O. Dulac, M. Kurthen, H. Lassmann, R. Mantegazza, J.-G. Villemure, R. Spreafico, et al.
Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European consensus statement
Brain, March 1, 2005; 128(3): 454 - 471.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. Watson, Y. Jiang, I. Bermudez, L. Houlihan, L. Clover, K. McKnight, J. H. Cross, I. K. Hart, A. Roubertie, J. Valmier, et al.
Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis
Neurology, July 13, 2004; 63(1): 43 - 50.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. A. Lozsadi, I. K. Hart, and A. P. Moore
Botulinum toxin A improves involuntary limb movements in Rasmussen syndrome
Neurology, April 13, 2004; 62(7): 1233 - 1234.
[Full Text] [PDF]

Home page
 NeurologyHome page
T. Granata, L. Fusco, G. Gobbi, E. Freri, F. Ragona, G. Broggi, R. Mantegazza, L. Giordano, F. Villani, G. Capovilla, et al.
Experience with immunomodulatory treatments in Rasmussen's encephalitis
Neurology, December 23, 2003; 61(12): 1807 - 1810.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
A. M. Devlin, J. H. Cross, W. Harkness, W. K. Chong, B. Harding, F. Vargha-Khadem, and B. G. R. Neville
Clinical outcomes of hemispherectomy for epilepsy in childhood and adolescence
Brain, March 1, 2003; 126(3): 556 - 566.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. Thomas, B. Zifkin, G. Ghetau, and O. Delalande
Persistence of ictal activity after functional hemispherectomy in Rasmussen syndrome
Neurology, January 14, 2003; 60(1): 140 - 142.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
C. G. Bien, G. Widman, H. Urbach, R. Sassen, S. Kuczaty, O. D. Wiestler, J. Schramm, and C. E. Elger
The natural history of Rasmussen's encephalitis
Brain, August 1, 2002; 125(8): 1751 - 1759.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al.
Intravenous immunoglobulin in neurological disease: a specialist review
J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S.E. Baranzini, K. Laxer, R. Saketkhoo, M.K. Elkins, J.M. Parent, R. Mantegazza, and J.R. Oksenberg
Analysis of antibody gene rearrangement, usage, and specificity in chronic focal encephalitis
Neurology, March 12, 2002; 58(5): 709 - 716.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. G. Bien, H. Urbach, M. Deckert, J. Schramm, O. D. Wiestler, H. Lassmann, and C. E. Elger
Diagnosis and staging of Rasmussen's encephalitis by serial MRI and histopathology
Neurology, January 22, 2002; 58(2): 250 - 257.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M.J. Hennessy, M. Koutroumanidis, A.F. Dean, J. Jarosz, R.D.C. Elwes, C.D. Binnie, and C.E. Polkey
Chronic encephalitis and temporal lobe epilepsy: A variant of Rasmussen's syndrome?
Neurology, March 13, 2001; 56(5): 678 - 681.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
M J Rood, J F Haverman, S G van Duinen, F C Breedveld, J J G M Verschuuren, and T W J Huizinga
CNS involvement in systemic lupus erythematosus: a case with remarkable histopathological findings
Ann Rheum Dis, March 1, 2001; 60(3): 299 - 300.
[Full Text] [PDF]

Home page
 NeurologyHome page
F. Villani, R. Spreafico, L. Farina, A.R. Giovagnoli, P. Bernasconi, T. Granata, and G. Avanzini
Positive response to immunomodulatory therapy in an adult patient with Rasmussen's encephalitis
Neurology, January 23, 2001; 56(2): 248 - 250.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
S. Vinjamuri, J P Leach, and I K Hart
Serial perfusion brain tomographic scans detect reversible focal ischaemia in Rasmussen's encephalitis
Postgrad. Med. J., January 1, 2000; 76(891): 33 - 35.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.